Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17016780 | 0.87 | KMT2A (0.34) | FFAR4FGFR2FGFR1KDM4EGAA | |
| SCHEMBL17016781 | 0.87 | KMT2A (0.36) | FFAR4FGFR2FGFR1KDM4EGAA | |
| SCHEMBL17016805 | 0.86 | TUBB1 (0.37) | ESR1FGFR2FGFR1KDM4EKMT2A | |
| SCHEMBL17016777 | 0.82 | KMT2A (0.36) | FFAR4FGFR2FGFR1KDM4EGAA | |
| SCHEMBL17016918 | 0.78 | FGFR2 (0.35) | FGFR2FGFR1KDM4EGAAKMT2A | |
| SCHEMBL17016783 | 0.78 | TUBB1 (0.34) | ESR1FGFR2FGFR1KDM4EGAA | |
| SCHEMBL16651803 | 0.75 | FFAR4 (0.40) | FFAR4ESR1FGFR2FGFR1KDM4E | |
| SCHEMBL1242705 | 0.74 | DRD1 (0.48) | FGFR2FGFR1KDM4EGAAKMT2A | |
| SCHEMBL17016782 | 0.74 | CHKA (0.31) | — | |
| SCHEMBL17016899 | 0.74 | ESR1 (0.33) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9404040-B2 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150232759-A1 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232759-A1 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | PYM1, CXCR1, LEO1 | FFAR4 828/4885ESR1 3452/4885FGFR2 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.